Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In August
Citius Oncology Inc CTOR
$0.59
▲ +3.22%
(+$0.02)
⬆️ Above Yest. High
🎢 High Beta
🗓️ Earnings Next Week
Open
$0.60
Prev Close
$0.57
Day Range
$0.59 – $0.60
52W Range
$0.49 – $2.33
Market Cap
$55.07M
Beta
3.44
EPS (TTM)
$-0.47
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-10-14 |
| Shares Out. | 92,980,000 |
| Website | citiusonc.com/ ↗ |
| Phone | 19089676677 |
| Revenue | $1.7M |
| Gross Profit | $1.3M |
| Net Income | -$26.6M |
| Total Assets | $100.7M |
| Total Liabilities | $65.4M |
| Equity | $35.3M |
About Citius Oncology Inc
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
Citius Oncology Inc is a publicly traded company under the ticker symbol CTOR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)